Doxribtimine

Doxribtimine

SCHEMBL8905917

CCO.Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

P

The experimentally established mechanism targets of Doxribtimine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
TK1 P04183 5/20 0.71
TK2 O00142 1/20 0.71
LMNA P02545 2/20 0.70
SMN1; SMN2 Q16637 2/20 0.70
ALOX12 P18054 1/20 0.66
ADRA1A P35348 1/20 0.66
ALB P02768 1/20 0.64
PKM P14618 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Doxribtimine SCHEMBL3437224 0.97 TK1 (0.73) TK1TK2LMNASMN1; SMN2ALOX12
Doxribtimine SCHEMBL10382149 0.97 TK1 (0.73) TK1TK2LMNASMN1; SMN2ALOX12
Doxribtimine SCHEMBL767986 0.97 TK1 (0.73) TK1TK2LMNASMN1; SMN2ALOX12
Doxribtimine SCHEMBL13497202 0.97 TK1 (0.73) TK1TK2LMNASMN1; SMN2ALOX12
Doxribtimine SCHEMBL12296879 0.97 TK1 (0.73) TK1TK2LMNASMN1; SMN2ALOX12
Doxribtimine SCHEMBL2722555 0.97 TK1 (0.73) TK1TK2LMNASMN1; SMN2ALOX12
Doxribtimine SCHEMBL14596596 0.97 TK1 (0.73) TK1TK2LMNASMN1; SMN2ALOX12
Doxribtimine SCHEMBL12718344 0.97 TK1 (0.73) TK1TK2LMNASMN1; SMN2ALOX12
Doxribtimine SCHEMBL21078835 0.97 TK1 (0.73) TK1TK2LMNASMN1; SMN2ALOX12
Doxribtimine SCHEMBL778861 0.97 TK1 (0.73) TK1TK2LMNASMN1; SMN2ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5677439-A PREVENTION GENE EXPRESSION SANOFI (FR) 1997-10-14 US disclosed
EP-0541722-B1 COMPOUNDS AND METHODS FOR INHIBITING GENE EXPRESSION STERLING WINTHROP INC (US) 1995-12-20 EP disclosed
EP-0541722-A1 COMPOUNDS AND METHODS FOR INHIBITING GENE EXPRESSION. STERLING WINTHROP INC (US) 1993-05-19 EP disclosed
WO-1992002534-A2 COMPOUNDS AND METHODS FOR INHIBITING GENE EXPRESSION STERLING DRUG, INC. (US) 1992-02-20 WO disclosed